IGEA Pharma N.V. (SWX:IGPH) entered into an agreement to acquire 66% stake in Meditalia Srl from from certain of the current shareholders for €8.6 million on November 20, 2019. At the closing of the transaction (the “Closing”), the Selling Shareholders will be entitled to receive 12.2 million new common shares of IGEA Pharma N.V. Under the terms of the Agreement, the Selling Shareholders have further committed to supporting IGEA’s funding in a maximum amount of up to €1 million, subject to the overall placement result. The Closing is subject to (i) the satisfaction of certain customary conditions for a transaction of this type, (ii) the approval by the companies’ respective general meetings and (iii) IGEA having secured additional funding prior to the Closing, including by way of issuance of additional shares or similar equity instruments. IGEA is expected to schedule its extraordinary general meeting by early 2020. The transaction is expected to complete by March 2020. IGEA Pharma N.V. (SWX:IGPH) cancelled the acquisition of 66% stake in Meditalia Srl from from certain of the current shareholders on November 20, 2020.